GLP-2 T — Research Peptide

For in-vitro laboratory research use only. Not for human consumption.

The incretin axis sits at the center of modern metabolic research. GLP-2 T is a synthetic dual receptor agonist that simultaneously engages the GIP and GLP-1 receptors — a mechanism that has positioned it as one of the most actively studied peptides in incretin biology heading into 2026.

What Is GLP-2 T?

GLP-2 T is a synthetic dual agonist designed to bind and activate both:

• GIPR (Glucose-Dependent Insulinotropic Polypeptide Receptor) — central to incretin signaling and energy metabolism
• GLP-1R (Glucagon-Like Peptide-1 Receptor) — associated with insulin secretion, gastric motility, and appetite regulation

By engaging both receptors with a single molecule, GLP-2 T allows researchers to investigate the synergy between these pathways under controlled conditions.

Mechanism of Action

GLP-1R Activation

GLP-1R activation in preclinical models is associated with glucose-dependent insulin secretion, slowed gastric emptying, and modulation of hypothalamic appetite circuits.

GIPR Activation

GIPR engagement adds an additional layer of incretin signaling, with effects on insulin sensitivity, adipose tissue lipid handling, and energy homeostasis observed in animal models.

Synergy of Dual Engagement

Preclinical research suggests that simultaneous GIPR and GLP-1R activation produces metabolic effects that exceed the sum of either pathway alone — a finding that has driven sustained interest in dual-agonist research compounds.

Key Areas of Preclinical Research

Insulin Sensitivity

Animal models have examined how dual incretin engagement influences peripheral insulin sensitivity, hepatic glucose output, and post-prandial glucose handling.

Adipose Tissue Metabolism

GLP-2 T has been studied for effects on adipocyte function, including lipid storage, lipolysis, and adipose-derived signaling factor expression.

Appetite and Energy Balance

Preclinical models have characterized GLP-2 T's effects on food intake, energy expenditure, and hypothalamic neuropeptide expression.

Comparative Incretin Research

GLP-2 T provides a useful research tool for comparing single-agonist (GLP-1 only) versus dual-agonist (GLP-1 + GIP) versus triple-agonist (GLP-3 R) outcomes.

GLP-2 T in Research Bundles

GLP-2 T is commonly studied alongside:

• GLP-3 R — for direct dual-vs-triple agonist comparison studies
• Tesamorelin — for combined incretin and GH axis investigation
• MOTS-c — for crosstalk studies between incretin and mitochondrial signaling

Sourcing Standards

Dual agonist peptides require precise synthesis to maintain receptor selectivity. Require:

• HPLC purity at 99%+
• Mass spectrometry confirmation of sequence
• Independent third-party COA from an accredited lab
• Lyophilized form with proper storage protocols

Excalibur Peptides' GLP-2 T is independently verified to 99%+ purity with full COA documentation.

View the GLP-2 T product page →

All products sold by Excalibur Peptides are intended for in-vitro laboratory research use only. Not for human dosing, injection, or ingestion.

Deeper Dive: The Molecular Architecture of GLP-2 T

The efficacy of GLP-2 T as a research tool stems from its sophisticated molecular design, which was engineered to achieve two primary objectives: balanced dual-receptor agonism and an extended pharmacokinetic half-life suitable for preclinical study protocols. Understanding this structure is key to appreciating its function in laboratory settings.

The Peptide Backbone: A GIP Foundation

GLP-2 T is a 39-amino acid linear peptide. Its primary sequence is based on the native human Glucose-Dependent Insulinotropic Polypeptide (GIP) sequence. This GIP foundation is crucial as it provides the inherent framework for high-affinity binding to the GIP receptor (GIPR). However, native GIP has a very short biological half-life, being rapidly degraded by the dipeptidyl peptidase-4 (DPP-4) enzyme. Furthermore, native GIP has negligible affinity for the GLP-1 receptor (GLP-1R).

To overcome these limitations for research purposes, several strategic modifications were made:

1. DPP-4 Resistance: The second amino acid in the sequence, Alanine, is replaced with a non-proteinogenic amino acid, 2-aminoisobutyric acid (Aib). The DPP-4 enzyme primarily cleaves peptides after the second position if it is an Alanine or Proline. The steric hindrance provided by the Aib residue effectively blocks DPP-4 enzymatic action, dramatically increasing the stability of the peptide backbone in biological fluids and cell culture media.

2. Introduction of GLP-1R Affinity: Several amino acid substitutions are made throughout the GIP sequence to introduce and balance affinity for the GLP-1R. These substitutions are informed by the known sequence homologies and differences between GIP and GLP-1 and their respective receptor-binding domains. This creates a single molecule that can effectively dock with and activate both GIPR and GLP-1R, a feat neither native peptide can accomplish. The resulting agonism is described as "unimolecular," meaning one molecule carries the functional properties of two.

The Fatty Acid Moiety: Engineering Half-Life

To further extend the peptide's duration of action for experimental purposes, a process called acylation is employed. A C20 fatty diacid linker is attached to the lysine residue at position 20 (Lys20) via a gamma-glutamic acid (γ-Glu) spacer. This modification serves a critical function:

• Albumin Binding: The long fatty acid chain allows the GLP-2 T molecule to non-covalently bind to circulating albumin, a large and abundant protein in plasma. This creates a circulating reservoir of the peptide. By binding to albumin, the peptide is shielded from renal clearance (filtration by the kidneys) and enzymatic degradation. The molecule slowly dissociates from albumin over time, becoming available to interact with its target receptors. This mechanism is fundamental to achieving the extended pharmacokinetic profile necessary for many preclinical study designs, which may require sustained receptor engagement over hours or days.

This dual-pronged approach—a stabilized peptide backbone with engineered dual-receptor affinity and a fatty acid moiety for half-life extension—results in a powerful and stable research compound. It allows for the sustained, simultaneous investigation of GIPR and GLP-1R signaling pathways in a variety of in-vitro and animal model systems.

Insights from Seminal Preclinical Literature

The scientific rationale for investigating dual GIP/GLP-1R agonists like GLP-2 T is built upon a foundation of extensive preclinical research. These studies, conducted in cell cultures and animal models, were instrumental in demonstrating the potential for synergistic metabolic effects beyond what could be achieved with single-agonist compounds.

The Re-evaluation of the GIP Receptor

For many years, the role of the GIP receptor in the context of certain metabolic disturbances was debated. While GIP is a potent incretin hormone, its insulinotropic effects were observed to be diminished in specific animal models of metabolic disease. This led to a period where GLP-1R was the primary focus of incretin-based research. However, studies using compounds like GLP-2 T challenged this paradigm. Research by Finan et al. (2013) using rodent models demonstrated that while chronic GIPR agonism alone could have neutral or even negative effects on body weight, co-activation of GIPR with GLP-1R resulted in a greater reduction in body mass and adiposity than GLP-1R agonism alone. This seminal work suggested that GIPR signaling, when combined with GLP-1R signaling, plays a crucial and synergistic role in regulating energy balance, forcing a scientific re-evaluation of GIP's function.

Delineating Synergy in Animal Models

Subsequent preclinical investigations focused on precisely how this synergy manifests. Studies in diet-induced obese (DIO) mice provided critical data. For example, research published by Frias et al. (2018) in the context of clinical trial background data discussed the underlying preclinical work, which showed that a dual agonist produced greater effects on glycemic control and body weight reduction in DIO mice compared to a selective GLP-1R agonist. These animal models allowed researchers to dissect the contributions of each pathway. They found that the GLP-1R component was a primary driver of reduced food intake and slowed gastric emptying, while the GIPR component appeared to enhance the effects on insulin sensitivity and potentially modulate fat metabolism within adipose tissue.

In a study by Coskun et al. (2018), the distribution and cellular effects of a dual GIP/GLP-1 receptor agonist were explored in mice. The study employed sophisticated imaging and analysis techniques to demonstrate that the compound engaged both receptors and that GIPR activation in adipose tissue was linked to improved metabolic parameters. This provided a mechanistic link between the compound's structure and its observed effects in preclinical models, suggesting GIPR's role may be particularly important in modulating lipid storage and energy expenditure. These findings in animal models are fundamental to the ongoing in-vitro research aimed at understanding how these pathways interact at the cellular level in adipocytes, pancreatic islets, and neuronal cell lines.

Analytical Quality Control: A Commitment to Research Integrity

The reliability of any in-vitro research hinges on the quality and characterization of the reagents used. For complex synthetic peptides like GLP-2 T, a multi-faceted analytical approach is not just best practice; it is essential for generating reproducible and valid data. At Excalibur Peptides, we provide a transparent overview of the rigorous testing methodologies applied to each batch of our research compounds. This ensures that the material a researcher receives is precisely what is needed for their experiments.

Purity Assessment via High-Performance Liquid Chromatography (HPLC)

HPLC is the gold standard for assessing the purity of synthetic peptides. This technique separates components of a mixture based on their chemical properties.

• Principle: A small amount of the reconstituted peptide is injected into a high-pressure stream of a liquid (the "mobile phase"). This mobile phase carries the sample through a column packed with a solid material (the "stationary phase"). For peptide analysis, reverse-phase HPLC (RP-HPLC) is typically used, where the stationary phase is nonpolar (hydrophobic) and the mobile phase is polar (e.g., a mixture of water and acetonitrile).
• Separation: Peptides and any synthesis-related impurities (e.g., truncated sequences, deletion sequences, or residual protecting groups) will interact differently with the stationary phase. The primary, correct peptide sequence will elute from the column at a characteristic time, known as its "retention time." Impurities will elute at different times.
• Detection & Quantification: As the components exit the column, they pass through a UV detector. The peptide bonds absorb UV light at a specific wavelength (typically 214-220 nm). The detector measures this absorbance, generating a signal that is plotted against time, creating a chromatogram. The main peak represents the target peptide, while smaller peaks represent impurities. Purity is calculated by integrating the area under the curve (AUC) of the main peak and expressing it as a percentage of the total area of all peaks.
• Excalibur's Standard: For GLP-2 T, our specification demands a purity of ≥99% as determined by HPLC, ensuring that confounding variables from impurities are minimized in sensitive assays.

Identity Confirmation via Mass Spectrometry (MS)

While HPLC confirms purity, it does not confirm identity. Mass Spectrometry is employed to verify that the primary peak from the HPLC is, in fact, the correct peptide by measuring its molecular weight with high precision.

• Principle: Mass spectrometry measures the mass-to-charge ratio (m/z) of ionized molecules. A purified sample (often taken directly from the main HPLC peak) is introduced into the mass spectrometer, where it is vaporized and ionized (e.g., by Electrospray Ionization, ESI).
• Analysis: These charged ions are then accelerated by an electric field into a mass analyzer, which separates them based on their m/z ratio. The detector records the abundance of ions at each m/z value, generating a mass spectrum.
• Verification: For GLP-2 T, the theoretical molecular weight is calculated based on its amino acid sequence and the attached fatty acid moiety. The experimentally measured mass from the MS analysis must match this theoretical mass within a very narrow tolerance. This confirms that the peptide was synthesized with the correct sequence and the modification is present.

Quantifying Critical Parameters for Assay Accuracy

Beyond purity and identity, other factors can significantly impact experimental outcomes.

• Peptide Content (Net Peptide): Lyophilized peptide powder is not 100% peptide. It contains counterions (like trifluoroacetate from the purification process) and bound water. Peptide content analysis, often determined by amino acid analysis (AAA) or quantitative NMR, measures the actual percentage of peptide by weight in the vial. This value is critical for researchers to accurately calculate the concentration when preparing stock solutions for their assays. For example, if a vial contains 10 mg of powder with a peptide content of 85%, it contains 8.5 mg of the active peptide.
• Water Content (Karl Fischer Titration): This method specifically quantifies the amount of water present in the lyophilized powder. Knowing this value is another key component in calculating accurate peptide concentrations for dosing in cell culture or other in-vitro systems.
• Endotoxin Testing (LAL Assay): Endotoxins (lipopolysaccharides from the cell walls of Gram-negative bacteria) are potent activators of the immune system. Even trace amounts can cause significant, non-specific responses in cell-based assays, confounding experimental results. The Limulus Amebocyte Lysate (LAL) test is an extremely sensitive assay used to ensure that endotoxin levels are below an acceptable threshold for research use, preserving the integrity of in-vitro experiments.

By combining these orthogonal analytical techniques—HPLC for purity, MS for identity, and specific assays for peptide content, water, and endotoxins—we provide a comprehensively characterized product that researchers can use with the highest degree of confidence.

Laboratory Handling and Reconstitution Protocol for In-Vitro Assays

Proper handling and reconstitution of lyophilized peptides like GLP-2 T are paramount to preserving their structural integrity and ensuring experimental reproducibility. The lyophilized powder is stable at low temperatures, but once in solution, its stability is dependent on proper technique and storage. The following guidelines are intended for preparing stock solutions for laboratory research applications, such as cell culture experiments, receptor binding assays, or enzyme kinetics studies.

Step 1: Pre-Reconstitution Equilibration

Before opening the vial, allow the lyophilized peptide to equilibrate to room temperature for at least 15-30 minutes. The vial is sealed under a partial vacuum and is cold from storage. Opening a cold vial can cause atmospheric moisture to condense inside, which can compromise the peptide's stability and affect the accuracy of weighing.

Step 2: Choosing the Appropriate Solvent

The choice of solvent is critical and depends on the peptide's specific sequence and the intended downstream application.

• For General Stock Solutions: For GLP-2 T, which is a relatively large and complex peptide, a slightly basic buffer is often preferred for initial solubilization to ensure the entire peptide, including its acidic fatty acid moiety, is fully dissolved. A small amount of a weak base like ammonium hydroxide (e.g., 0.1%) or a buffer like 10mM HEPES at pH 8.0 can be effective.
• Alternative for Less Concentrated Solutions: For many applications, sterile, high-purity water (e.g., Milli-Q or WFI-grade) can be used, although dissolution might be slower. It is generally recommended to avoid using saline or Phosphate Buffered Saline (PBS) for the initial high-concentration stock, as salts can sometimes promote peptide aggregation. Dilutions into PBS or other physiological buffers can be made from a concentrated stock solution prepared in water or a weak buffer.
• Check Solubility Information: Always refer to the product-specific COA or technical data sheet for any provided solubility guidance.

Step 3: Reconstitution for a Concentrated Stock Solution

Accurate calculations are essential for creating a stock solution of a known concentration.

1. Determine Net Peptide Amount: Refer to the Certificate of Analysis (COA) for the Net Peptide Content. For example, a vial labeled "10 mg" (gross weight) with a net peptide content of 85% contains 8.5 mg of active peptide. All calculations must be based on this net peptide weight.

2. Calculate Required Solvent Volume:

   • Formula: Volume (L) = [Net Peptide Weight (g)] / [Desired Concentration (mol/L) * Molecular Weight (g/mol)]
   • Example: To make a 1 mM stock solution of GLP-2 T (approx. MW ~4813.5 g/mol) from a vial containing 8.5 mg (0.0085 g) of net peptide:
     • Volume (L) = 0.0085 g / (0.001 mol/L * 4813.5 g/mol)
     • Volume (L) = 0.00176 L = 1.76 mL
   • Therefore, adding 1.76 mL of the chosen solvent to the vial will yield a stock solution with a concentration of 1 mM.

3. Mixing Technique: Add the calculated volume of solvent to the vial using a calibrated pipette. Do NOT vortex or shake vigorously. Many peptides, especially larger ones, can be damaged by shearing forces or can aggregate. Instead, gently swirl the vial or roll it between your palms. If the peptide is slow to dissolve, it can be left at 4°C for a short period with occasional gentle agitation. Sonication is generally not recommended unless specified for a particular peptide.

Step 4: Aliquoting and Storage

To preserve the integrity of the peptide and avoid repeated freeze-thaw cycles, the stock solution should be immediately aliquoted.

• Aliquoting: Divide the stock solution into smaller, single-use volumes in low-protein-binding microcentrifuge tubes. The volume of each aliquot should correspond to what is typically used for a single experiment or to prepare a working solution for a set of experiments. A common aliquot volume might be 10-50 µL.
• Short-Term Storage: For use within 1-5 days, aliquots of the stock solution can be stored at 2-8°C.
• Long-Term Storage: For storage longer than a week, the aliquots must be flash-frozen and stored at -20°C or preferably -80°C. Stored this way, the peptide solution can remain stable for several months. Avoid using frost-free freezers, as their temperature fluctuations can damage the peptide.

By following this meticulous laboratory protocol, researchers can ensure their GLP-2 T stock solutions are accurately prepared and stably stored, providing a reliable foundation for high-quality in-vitro data.

Comparative Framework: GLP-2 T vs. Other Incretin Research Peptides

To contextualize the unique research applications of GLP-2 T, it is useful to compare it with other prominent incretin-related peptides used in metabolic research: selective GLP-1R agonists and the triple-agonist GLP-3 R.

Expanded Frequently Asked Questions (FAQ) for Researchers

Q1: What is the molecular weight of the GLP-2 T supplied by Excalibur Peptides? A: The theoretical molecular weight of GLP-2 T is approximately 4813.5 g/mol (Da). The exact measured mass for each batch is confirmed via Mass Spectrometry and is reported on the Certificate of Analysis (COA) that accompanies the product.

Q2: What is the primary difference in research application between GLP-2 T and GLP-3 R? A: The primary difference lies in the third receptor target. GLP-2 T is a dual agonist for the GIP and GLP-1 receptors, making it ideal for studying the synergy between the two core incretin pathways. GLP-3 R is a triple agonist, adding the Glucagon Receptor (GCGR) to the GIPR/GLP-1R targets. GLP-3 R is therefore used in research designed to investigate the additional metabolic effects of GCGR activation—such as increased energy expenditure and effects on liver metabolism—on top of the dual-incretin platform.

Q3: How should I store the lyophilized GLP-2 T vial upon receipt? A: The lyophilized peptide is shipped on cold packs and should be transferred immediately to a controlled cold-storage environment. For long-term storage (months to years), store the unopened vial at -20°C or, for optimal stability, at -80°C. Keep it protected from light.

Q4: Is it safe to use a vortex mixer to dissolve the peptide? A: We strongly advise against vortexing or vigorous shaking. GLP-2 T is a large, complex peptide, and the mechanical shear forces generated by a vortex can lead to aggregation or denaturation, reducing its biological activity. The recommended method is gentle swirling or inversion until the peptide is fully dissolved.

Q5: Why is the peptide acylated with a fatty acid? What does this mean for in-vitro studies? A: The fatty acid moiety is engineered to allow the peptide to bind to albumin. In animal models, this dramatically extends its half-life. In in-vitro studies using cell culture media containing serum (which contains albumin), this binding will also occur. Researchers should be aware of this and may need to account for it in their experimental design. For serum-free culture conditions or purified receptor assays, the peptide's activity will be more direct as there is no albumin to form a circulating reservoir.

Q6: What is the difference between "peptide purity" and "peptide content"? They are both percentages. A: This is a critical distinction for accurate lab work. Purity, determined by HPLC, refers to how much of the peptide material is the correct, full-length sequence versus synthesis-related impurities (e.g., shorter or modified sequences). A 99% purity means 99% of the peptides in the vial are the correct molecule. Content (or net peptide weight) refers to the percentage of the total powder weight in the vial that is actual peptide, versus other things like water and counterions from the purification process. A vial with 85% peptide content means that for every 10 mg of powder, 8.5 mg is the peptide. Both values are required to prepare an accurate final concentration.

Q7: Can I reconstitute GLP-2 T in PBS? A: While final working solutions for cell assays are often made in PBS, we do not recommend using PBS for creating the initial, highly concentrated stock solution. The salts in PBS can sometimes reduce solubility or promote aggregation of certain peptides at high concentrations. It is better practice to reconstitute in sterile, high-purity water or a weak buffer (e.g., 10mM HEPES, pH ~8.0), and then dilute this stock into your experimental buffer (like PBS or cell culture medium) to achieve the final working concentration.

Q8: Why is endotoxin testing so important if I am not working with immune cells? A: Endotoxins can have pleiotropic effects on many cell types, not just macrophages or other immune cells. They can trigger stress-response pathways, alter gene expression, and induce low-level inflammation or cytotoxicity that can confound the specific results of your peptide experiment. For example, an endotoxin-induced change in cellular metabolism could be mistakenly attributed to the action of GLP-2 T. Using low-endotoxin reagents is a cornerstone of good cell culture practice and data integrity.

Q9: The COA mentions trifluoroacetate (TFA) as a counterion. Will this affect my experiments? A: TFA is a common counterion resulting from the RP-HPLC purification process. In the lyophilized powder, it forms a salt with the basic amino acid residues of the peptide. When the peptide is reconstituted and diluted to typical nanomolar or low micromolar working concentrations for in-vitro assays, the final TFA concentration is extremely low and generally considered to have a negligible effect on most biological systems. However, for exceptionally sensitive assays, dialysis or buffer exchange of the stock solution can be considered.

Q10: How many freeze-thaw cycles can a reconstituted aliquot of GLP-2 T tolerate? A: We strongly recommend a "single-use" aliquot strategy to avoid freeze-thaw cycles altogether. Each cycle of freezing and thawing subjects the peptide to mechanical stress from ice crystal formation and pH shifts, which can lead to aggregation and degradation. If absolutely necessary, 1-2 cycles may be tolerated, but it is not ideal and may compromise activity. Preparing appropriately sized aliquots from the outset is the best protocol to ensure maximum peptide stability and experimental consistency.

Glossary of Technical Terms

• Agonist: A molecule (ligand) that binds to a receptor and activates it, producing a biological response. GLP-2 T is an agonist for both GIPR and GLP-1R.
• Acylation: The chemical process of attaching a fatty acid chain (an acyl group) to a molecule, typically to a peptide's amino acid side chain (e.g., lysine). This is done to increase binding to serum albumin.
• cAMP (Cyclic Adenosine Monophosphate): A second messenger molecule important in many biological processes. Both GIPR and GLP-1R activation lead to an increase in intracellular cAMP levels.
• DPP-4 (Dipeptidyl Peptidase-4): An enzyme that rapidly degrades many native peptide hormones, including GLP-1 and GIP, by cleaving them after the second amino acid. Synthetic peptides like GLP-2 T are modified to be resistant to DPP-4.
• Endotoxin: A lipopolysaccharide (LPS) component of the outer membrane of Gram-negative bacteria. Endotoxins are potent immune stimulants and can confound results in cell-based assays.
• G-Protein Coupled Receptor (GPCR): A large family of cell surface receptors that transmit signals from outside the cell to the inside. GIPR, GLP-1R, and GCGR are all members of the Class B GPCR family.
• HPLC (High-Performance Liquid Chromatography): A powerful analytical chemistry technique used to separate, identify, and quantify each component in a mixture. It is the standard method for determining peptide purity.
• Incretin: A class of metabolic hormones that are released from the gut after eating and stimulate a decrease in blood glucose levels. GIP and GLP-1 are the two primary incretin hormones.
• In-Vitro: Refers to research conducted in a controlled environment outside of a living organism, such as in a test tube or a cell culture dish.
• Ligand: A substance that forms a complex with a biomolecule (like a receptor) to serve a biological purpose.
• Lyophilization: A freeze-drying process used to remove water from a product. It involves freezing the material and then reducing the surrounding pressure to allow the frozen water to sublave directly from a solid to a gas. This makes peptides stable for long-term storage.
• Mass Spectrometry (MS): An analytical technique that measures the mass-to-charge ratio of ions. It is used to confirm the molecular weight of a peptide, thereby verifying its identity and correct synthesis.
• Pharmacokinetics (PK): The study of how an organism's system affects a compound, in terms of absorption, distribution, metabolism, and excretion. In research, this relates to a compound's half-life and duration of action.
• Preclinical Model: A non-human system used in research to study a biological phenomenon. This includes studies in cell culture (in-vitro) and in animals (in-vivo), such as mice or rats.
• Receptor: A protein molecule, usually on the surface of or within a cell, that receives chemical signals from outside the cell.

References

• Coskun, T., Sloop, K. W., Loghin, C., et al. (2018). LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to launch. Molecular Metabolism, 18, 3-14.
• Finan, B., Ma, T., Ottaway, N., et al. (2013). Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Science Translational Medicine, 5(209), 209ra151.
• Frias, J. P., Nauck, M. A., Ehrlich, J., et al. (2018). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. The New England Journal of Medicine, 379(21), 2007-2018. [Note: This clinical paper provides background on preclinical data motivating the study].

All compounds, including GLP-2 T, sold by Excalibur Peptides are synthesized for and strictly intended for in-vitro laboratory research purposes only. These materials are not intended for human or veterinary use. They are not drugs, cosmetics, food additives, or any other class of product meant for consumption. The information provided is for educational and research-planning purposes and does not constitute an endorsement of any particular experimental protocol. Researchers are responsible for adhering to all local, state, and federal regulations governing the handling, storage, and use of research chemicals. Any questions regarding product specifications or quality control should be directed to our support team at info@excaliburpeptides.com.

Sourcing Philosophy and Cold Chain Logistics for Research Peptides

The integrity of a complex synthetic peptide like GLP-2 T is determined long before it reaches a researcher's laboratory. Its quality is a direct reflection of the materials and processes used in its creation and subsequent handling. The synthesis of a 39-amino acid peptide with a C20 fatty acid modification is a multi-step process where precision is paramount. It begins with the selection of high-grade, protected amino acid precursors and specialized reagents, including the non-proteinogenic 2-aminoisobutyric acid (Aib) required for DPP-4 resistance. Any impurities in these starting materials can lead to the formation of deletion sequences or other incorrect products that are difficult to separate from the final peptide.

Following solid-phase peptide synthesis (SPPS), the crude peptide is cleaved from the resin and subjected to rigorous purification, primarily using reverse-phase high-performance liquid chromatography (RP-HPLC). This critical step isolates the full-length, correctly modified peptide from a mixture of shorter sequences, incompletely modified peptides, and other process-related impurities. Only fractions meeting a stringent purity threshold are pooled. The purified peptide, dissolved in an aqueous solvent, is then subjected to lyophilization (freeze-drying). This process removes the solvent under deep vacuum, yielding a stable, fluffy powder that is far less susceptible to degradation than its solution-state counterpart.

Maintaining this hard-won stability requires an unbroken cold chain. From our facility to the research institution, GLP-2 T is handled with strict temperature control. Each vial is securely sealed to protect it from moisture and oxygen, then packaged in an insulated shipping container with frozen gel packs. This ensures that the peptide's temperature is maintained well below ambient levels during transit, minimizing any potential for degradation. Upon receipt, it is the researcher's responsibility to immediately transfer the unopened vial to a designated laboratory freezer (-20°C or -80°C) to preserve its long-term integrity until it is prepared for in-vitro use.

Designing In-Vitro Experiments with GLP-2 T

The utility of GLP-2 T as a research tool is realized through carefully designed in-vitro assays. These experiments allow for the precise interrogation of its molecular mechanisms in a controlled setting, free from the systemic complexities of a whole-organism model.

Selecting Appropriate Cell Models

The choice of cell model is fundamental to the research question being asked.

• Recombinant Receptor-Specific Models: For studies focused on pure receptor pharmacology (e.g., determining binding affinity or potency), non-native cell lines are often used. Chinese Hamster Ovary (CHO-K1) or Human Embryonic Kidney (HEK293) cells are common choices. These cells typically have low endogenous expression of incretin receptors. Researchers use them after they have been stably transfected to express the human GIP receptor, the human GLP-1 receptor, or both. This allows for the isolated study of GLP-2 T's interaction with each receptor target without interference from other signaling systems.
• Endogenous Expression Models: To investigate the functional consequences of receptor activation in a more biologically relevant context, cell lines that endogenously express these receptors are required. Examples include pancreatic beta-cell lines (e.g., INS-1, MIN6) for studying insulin secretion, adipocyte cell lines (e.g., differentiated 3T3-L1 cells) for investigating lipid metabolism and adipokine secretion, or hypothalamic neuronal cell lines for exploring central signaling pathways.

Measuring Receptor Activation and Downstream Signaling

Once a cell model is chosen, the primary step is to quantify the peptide's effect.

• cAMP Accumulation Assays: Since both GIPR and GLP-1R are Gs-protein coupled receptors, their activation leads to a rise in the intracellular second messenger cyclic AMP (cAMP). A cAMP assay is therefore a workhorse for characterizing GLP-2 T. In such an experiment, cells are treated with a range of GLP-2 T concentrations (a dose-response curve). After incubation, the cells are lysed, and the amount of cAMP produced is quantified using a competitive immunoassay, often one employing a sensitive detection method like HTRF (Homogeneous Time-Resolved Fluorescence). The resulting data allows for the calculation of the EC50 value—the concentration of GLP-2 T that produces 50% of the maximal response—which is a key measure of the peptide's potency at its target(s).
• Phenotypic Assays: Beyond second messengers, researchers can measure downstream functional outcomes. In a pancreatic INS-1 cell line, for instance, a glucose-stimulated insulin secretion (GSIS) assay can be performed. Cells would be exposed to GLP-2 T in the presence of both low and high glucose concentrations to determine how dual agonism modulates the insulin secretory response. In differentiated 3T3-L1 adipocytes, researchers might use qPCR to measure changes in the expression of genes involved in lipogenesis or lipolysis, or use an ELISA to quantify the secretion of adiponectin into the cell culture medium.

Advanced Concept: Exploring Receptor Bias with Dual Agonists

The terms "agonist" and "dual agonist" imply a straightforward activation of receptors. However, the field of G-protein coupled receptor (GPCR) pharmacology has revealed a more nuanced reality known as biased agonism or "functional selectivity." This concept is highly relevant to the advanced characterization of molecules like GLP-2 T.

A GPCR, upon binding an agonist, can adopt multiple active conformations, allowing it to couple to different intracellular signaling partners. The two most studied pathways are:

1. G-Protein Signaling: The canonical pathway where the receptor activates a G-protein (like Gs for GIPR and GLP-1R), which in turn modulates the activity of an effector enzyme like adenylyl cyclase to produce cAMP.
2. β-Arrestin Signaling: An alternative pathway where the activated receptor recruits proteins called β-arrestins. This can lead to receptor desensitization and internalization, but also initiates a distinct set of G-protein-independent signaling cascades.

Biased agonism describes a ligand's ability to preferentially activate one of these pathways over the other, relative to a balanced or reference agonist. A molecule like GLP-2 T might be a "balanced" agonist at the GLP-1R, activating both cAMP and β-arrestin pathways to a similar degree. However, it could be a "G-protein biased" agonist at the GIPR, potently stimulating cAMP production while only weakly recruiting β-arrestin.

For in-vitro research, this is critically important. The distinct cellular outcomes observed with GLP-2 T may be a result not just of activating two different receptors, but of activating them with different signaling textures. A researcher could investigate this by directly comparing the dose-response curves for cAMP production (via HTRF/ELISA) and β-arrestin recruitment (e.g., using a PathHunter or Tango assay system) for GLP-2 T at both the GIPR and GLP-1R in transfected cells. Calculating the "bias factor" from the relative potencies in these orthogonal assays provides a quantitative measure of the compound's signaling preference, offering a deeper mechanistic understanding of its action at the cellular level.

Structural Distinctions: GLP-2 T vs. GLP-3 R

While both GLP-2 T and GLP-3 R are acylated, long-acting multi-receptor agonists used in advanced metabolic research, their specific targets and applications are dictated by fundamental differences in their molecular architecture. The following table contrasts their key structural features.

All compounds, including GLP-2 T, sold by Excalibur Peptides are synthesized for and strictly intended for in-vitro laboratory research purposes only. These materials are not intended for human or veterinary use. They are not drugs, cosmetics, food additives, or any other class of product meant for consumption. The information provided is for educational and research-planning purposes and does not constitute an endorsement of any particular experimental protocol. Researchers are responsible for adhering to all local, state, and federal regulations governing the handling, storage, and use of research chemicals. Any questions regarding product specifications or quality control should be directed to our support team at info@excaliburpeptides.com.